Aceragen | IDRA - Passivo Circulante



Passivo Circulante Alterar Data
Abbott USD 16.5B 1.91B 2025-12
Agenus USD 323.49M 36.36M 2025-12
Alnylam Pharmaceuticals USD 1.47B 89.13M 2025-12
Alterity Therapeutics Limited AUD 1.73M 2.77M 2025-12
Amgen USD 25.49B 3.7B 2025-12
Biogen USD 3.35B 59.4M 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Cipla INR 62.97B 8.13B 2025-09
Clal Biotechnology ILS 6.66M 3.75M 2023-12
Compugen USD 22.57M 2.29M 2025-12
CSL USD 4.61B 207M 2025-12
Eli Lilly USD 35.23B 4.91B 2025-12
Gilead Sciences USD 11.81B 485M 2025-12
GlaxoSmithKline GBP 21.39B 57M 2025-12
Grifols EUR 2.37B 156.97M 2025-12
Merck USD 28.63B 2.59B 2025-09
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Pfizer USD 36.6B 1.13B 2025-09
Roche Holding CHF 28B 421M 2025-12
Sarepta Therapeutics USD 1.1B 173.86M 2025-12
Ultragenyx Pharmaceutical USD 340.02M 46.78M 2025-09
X T L Biopharmaceuticals USD 761K 1.45M 2025-06